Pfizer Inc.

NYSE:PFE

Drug Manufacturers - General

Healthcare
$28.06 -2.72%

-$0.71 today

Market cap
$159.94B
Beta
0.29
P/E (TTM)
19.2
EPS (TTM)
$1.32
Dividend yield
6.82%
52W Low $23.11High $28.75

Volume 37.37M

Average 36.66M

PFE Pre-Tax Margin

Income before tax as a percentage of revenue.

Pfizer Inc.NYSE: PFE

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to -4.3%

Pre-tax margin was -4.3% in Q2 FY2026, down 25.1 pp from a year earlier. On a trailing-twelve-month basis it was 6.6%, down 9.9 pp year over year. Over 3 fiscal years it narrowed by 22.3 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-4.3%-26.3 pp QoQ
Last fiscal yearDec 2025
12.0%-0.6 pp YoY
LTMJun 2026
6.6%-9.9 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-25.1 pp——
1 year-0.6 pp——
3 years-22.3 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
12.0%
Year-over-year change
-0.6pp

Pre-Tax Margin vs competitors

How PFE compares with its peers on the latest reported figures

  • PFE's LTM Jun 2026 pre-tax margin of 6.6% is the 10th highest of the 11 companies compared; the peer median is 18.6%.
  • Its year-over-year change of -9.9 pp is the 8th highest of 11, against a peer median of +0.6 pp.
  • Over three fiscal years its change of -22.3 pp compares with a peer median of +7.5 pp.
PFE Competitors Peer median
Pre-Tax Margin for PFE and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202642.2% +10.5 pp+15.6 pp
NVSNovartis AGLTM Jun 202627.9% -0.4 pp+13.5 pp
BMYBristol-Myers Squibb CompanyLTM Jun 202624.2% +10.4 pp+2.6 pp
AZNAstraZeneca PLCLTM Sep 202621.3% +1.6 pp+15.5 pp
ABBVAbbVie Inc.LTM Sep 202619.4% +16.6 pp-12.4 pp
JNJJohnson & JohnsonLTM Sep 202617.9% -16.3 pp+10.4 pp
GSKGSK plcLTM Jun 202617.8% +3.2 pp+3.5 pp
SNYSanofiLTM Jun 202610.6% -7.2 pp-11.7 pp
MRKMerck & Co., Inc.LTM Jun 20269.0% -21.1 pp+4.7 pp
PFEPfizer Inc.LTM Jun 20266.6% -9.9 pp-22.3 pp
GILDGilead Sciences, Inc.LTM Jun 2026-6.4% -31.4 pp+12.0 pp
Peer median (excluding PFE) 18.6%+0.6 pp+7.5 pp

Competitors are the stored peer set for PFE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.29B101.18B59.55B63.63B62.58B
Cost of Revenue30.82B34.34B24.95B17.85B16.07B
Gross Profit50.47B66.83B34.6B45.78B46.51B
Gross Margin62.1%66.1%58.1%71.9%74.3%
Research & Development13.83B11.43B10.68B10.82B10.44B
Selling, General & Admin12.7B13.68B14.77B14.73B13.79B
Operating Expenses30.23B28.71B30.18B30.84B29.11B
Depreciation & Amortization5.19B5.06B6.29B7.01B6.59B
EBITDA30.79B41.03B9.56B18.13B16.78B
EBITDA Margin37.9%40.6%16.0%28.5%26.8%
Operating Income20.24B38.12B4.42B14.94B17.41B
Operating Margin24.9%37.7%7.4%23.5%27.8%
Interest Income36M251M1.62B545M603M
Interest Expense1.29B1.24B2.21B3.09B2.67B
Other Income / Expenses4.08B(3.39B)(3.36B)(6.92B)(9.89B)
Income Before Tax24.31B34.73B1.06B8.02B7.52B
Pre-Tax Margin29.9%34.3%1.8%12.6%12.0%
Income Tax Expense1.85B3.33B(1.12B)(28M)(266M)
Net Income21.98B31.37B2.12B8.03B7.77B
Net Margin27.0%31.0%3.6%12.6%12.4%
EPS (Basic)3.955.590.381.421.36
EPS (Diluted)3.885.470.371.411.36
Weighted Avg Shares5.6B5.61B5.64B5.66B5.68B
Weighted Avg Shares (Diluted)5.71B5.73B5.71B5.7B5.69B

Pfizer Inc.

NYSE:PFE

Intrinsic Alpha fair value

Locked

Current Price

$28.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.